BiotechTube
Cerovations

Cerovations

Memphis, United States· Est.
cerovations.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cerovations is a private, pre-revenue medical device startup targeting the high-need area of severe traumatic brain injury (TBI) management. Its lead innovation, the OsmoFlo™ Bimodal EVD System, has earned FDA Breakthrough Device designation and is supported by an $8M NIH SBIR grant. The company, founded by experienced medtech executives and a clinician-inventor, is preparing for near-term first-in-human clinical trials through the prestigious TRACK-TBI network, aiming to address the significant mortality and poor outcomes associated with treatment-resistant intracranial hypertension.

Traumatic Brain InjuryNeurocritical Care

Technology Platform

The OsmoFlo™ Bimodal EVD System, a medical device that combines traditional cerebrospinal fluid (CSF) drainage with a novel osmotic therapy modality. The system removes water from CSF as vapor to increase CSF osmolarity, creating an osmotic gradient designed to draw water out of edematous brain tissue to reduce intracranial pressure.

Opportunities

The primary opportunity lies in addressing the vast unmet need in severe TBI, where current outcomes are poor.
Success with the lead indication could enable expansion into other neurocritical conditions involving cerebral edema, such as stroke.
The FDA Breakthrough Device designation provides a pathway for expedited review and potential premium pricing.

Risk Factors

Key risks include the clinical failure of its novel osmotic mechanism in human trials, regulatory hurdles despite the Breakthrough designation, and the challenge of driving adoption in a conservative ICU setting against established, lower-cost EVDs.
The company also faces future financing risk after its NIH grant is depleted.

Competitive Landscape

Competition includes standard EVD systems (a commodity market) and other therapies for refractory ICP like decompressive craniectomy. The OsmoFlo system's primary competition is the clinical inertia against adopting new, potentially more complex devices. It may face future competition from other companies developing advanced cerebral edema management technologies.

More companies in Neuroscience & CNS →More companies in United States →